744185
Last Update Posted: 2026-06-01
Recruiting has ended
All Genders accepted | Under 4 months |
14 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
Propranolol in Capillary Hemangiomas
The investigators observed that Propranolol, a beta-blocker commonly used in children was efficient to control the growth of alarming hemangiomas of the face.
The primary objective of this study is to determine the efficiency of 1 month-early treatment of propranolol in infants aged less than 4 months affected by an hemangioma without any consequences on vital or functional structure and not justifying corticosteroids.
The secondary objectives are:
* the kinetic of the hemangioma evolution in infants treated by propranolol * Observance * Safety
The investigators observed that Propranolol, a beta-blocker commonly used in children was efficient to control the growth of alarming hemangiomas of the face.
The primary objective of this study is to determine the efficiency of 1 month-early treatment of propranolol in infants aged less than 4 months affected by an hemangioma without any consequences on vital or functional structure and not justifying corticosteroids.
The secondary objectives are:
* the kinetic of the hemangioma evolution in infants treated by propranolol * Observance * Safety
Eligibility
Relevant conditions:
Hemangioma, Capillary
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the study if you think are close to fitting criteria.
locations
Data sourced from ClinicalTrials.gov